Srikala S Sridhar Selected Research

Srikala S Sridhar Research Topics

Disease

50	Neoplasms (Cancer) 05/2024 - 04/2005
37	Urinary Bladder Neoplasms (Bladder Cancer) 10/2023 - 09/2013
36	Carcinoma (Carcinomatosis) 03/2024 - 04/2013
33	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 12/2010
12	Neoplasm Metastasis (Metastasis) 03/2024 - 04/2013
8	Disease Progression 09/2023 - 05/2006
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2024 - 04/2005
4	Breast Neoplasms (Breast Cancer) 04/2019 - 12/2010
3	Pain (Aches) 02/2024 - 10/2014
2	Urologic Neoplasms (Urological Cancer) 02/2024 - 01/2023
2	Hydronephrosis 01/2023 - 01/2021
2	Margins of Excision 01/2023 - 01/2018
2	Fatigue 01/2023 - 04/2015
2	COVID-19 01/2023 - 05/2020
2	Febrile Neutropenia 11/2015 - 01/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2006 - 07/2003
2	Lung Neoplasms (Lung Cancer) 12/2003 - 08/2003
1	Chronic Renal Insufficiency 05/2024
1	Neoplasm Micrometastasis 01/2023
1	Nausea 01/2023
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Diarrhea 01/2022

Drug/Important Bio-Agent (IBA)

16	PlatinumIBA 05/2024 - 05/2006
16	Cisplatin (Platino)FDA LinkGeneric 05/2024 - 02/2015
14	Docetaxel (Taxotere)FDA Link 01/2023 - 04/2011
13	Biomarkers (Surrogate Marker)IBA 03/2024 - 09/2012
7	avelumabIBA 09/2023 - 01/2020
5	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2020
5	AndrogensIBA 01/2023 - 02/2016
5	abirateroneIBA 01/2020 - 09/2014
4	Androgen Receptors (Androgen Receptor)IBA 03/2024 - 01/2023
4	Hormones (Hormone)IBA 12/2023 - 01/2016
4	durvalumabIBA 09/2023 - 09/2017
3	enfortumab vedotinIBA 02/2024 - 01/2020
3	Gemcitabine FDA Link 11/2022 - 01/2020
3	Carboplatin (JM8)FDA LinkGeneric 11/2022 - 01/2020
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2018
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021 - 01/2020
3	cabazitaxel FDA Link 01/2021 - 03/2016
3	130-nm albumin-bound paclitaxelIBA 01/2021 - 07/2013
3	B7-H1 AntigenIBA 01/2021 - 01/2017
3	cediranib (AZD2171)IBA 11/2014 - 08/2013
3	Angiogenesis InhibitorsIBA 11/2014 - 08/2003
2	infigratinibIBA 04/2024 - 07/2022
2	tremelimumabIBA 09/2023 - 04/2019
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 01/2021
2	Radium-223IBA 01/2021 - 09/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 11/2020
2	AlbuminsIBA 01/2020 - 07/2013
2	Therapeutic UsesIBA 10/2019 - 01/2017
2	Hemoglobins (Hemoglobin)IBA 04/2015 - 04/2013
2	Abiraterone AcetateIBA 10/2014 - 09/2014
2	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 10/2014 - 09/2014
2	Lapatinib (GW572016)FDA Link 01/2012 - 12/2010
2	Sorafenib (BAY 43-9006)FDA Link 10/2011 - 04/2005
2	Epidermal Growth Factor (EGF)IBA 12/2010 - 07/2003
2	Celecoxib (Celebrex)FDA Link 12/2003 - 08/2003
2	IntegrinsIBA 12/2003 - 08/2003
2	O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA 12/2003 - 08/2003
2	N-acetylcochinol-O-phosphateIBA 12/2003 - 08/2003
2	squalamineIBA 12/2003 - 08/2003
1	rucaparibIBA 01/2023
1	CarcinogensIBA 01/2023
1	Indicators and Reagents (Reagents)IBA 01/2023
1	NivolumabIBA 02/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Cell-Free Nucleic AcidsIBA 01/2022
1	octaneIBA 01/2022
1	CreatinineIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	EnzymesIBA 01/2021
1	mesoglycanIBA 01/2021
1	NectinsIBA 08/2020
1	LigandsIBA 01/2020
1	enzalutamideIBA 01/2020
1	Serum AlbuminIBA 01/2020
1	Pantoprazole (Protonix)FDA LinkGeneric 01/2019
1	Biological FactorsIBA 01/2017
1	atezolizumabIBA 01/2017
1	Testosterone (Sustanon)FDA Link 02/2016
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 02/2016
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2016
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2016
1	IcrucumabIBA 01/2016
1	RamucirumabIBA 01/2016

Therapy/Procedure

42	Drug Therapy (Chemotherapy) 05/2024 - 05/2006
40	Therapeutics 03/2024 - 07/2003
22	Neoadjuvant Therapy 10/2023 - 09/2013
22	Castration 01/2023 - 04/2011
20	Cystectomy 10/2023 - 02/2012
5	Immunotherapy 01/2024 - 01/2017
5	Adjuvant Chemotherapy 01/2023 - 05/2013
2	Combination Drug Therapy (Combination Chemotherapy) 05/2024 - 01/2021
2	Aftercare (After-Treatment) 01/2023 - 12/2020
2	Radiotherapy 01/2021 - 07/2017
1	Chemoradiotherapy 02/2019
1	Nephroureterectomy 01/2018
1	Transurethral Resection of Bladder 07/2017
1	Continuity of Patient Care 01/2017
1	Injections 02/2016